<DOC>
	<DOC>NCT00580021</DOC>
	<brief_summary>Compare the clinical characteristics and post-surgical outcomes (overall survival)of pancreatic cancer patients of Ashkenazi descent with or without germline founder mutations in BRCA1 or BRCA2 . Compare the clinical characteristics and outcomes (time to progression) of breast cancer patients of Ashkenazi descent with or without germline founder mutations in BRCA1 or BRCA2 receiving paclitaxel chemotherapy for metastatic disease.</brief_summary>
	<brief_title>Clinical Outcomes in Hereditary Cancer</brief_title>
	<detailed_description>Compare the clinical characteristics and post-surgical outcomes (overall survival)of pancreatic cancer patients of Ashkenazi descent with or without germline founder mutations in BRCA1 or BRCA2 . Compare the clinical characteristics and outcomes (time to progression) of breast cancer patients of Ashkenazi descent with or without germline founder mutations in BRCA1 or BRCA2 receiving paclitaxel chemotherapy for metastatic disease.</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Included in DB036303 Jewish religious preference at registration Archival material available for testing Adequate postsurgical followup Jewish religious preference at registration Archival material available for testing Adequate followup to determine time to progression Subjects will not be included in the analyses if a DNA sample cannot be obtained.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Ashkenazi ancestry</keyword>
	<keyword>mutations in BRCA1 or BRCA2</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
</DOC>